years). Highest number of patients falls in other categories (23.9%) including neuropathy, myopathy, spinal muscular atrophy, sepsis and TB spine, followed by GBS (18.88%), TN (12.76%), hypokalemic hypotonia…
Guillan-Barre Syndrome (GBS) in 56.3%, Duchene Muscular Dystrophy (DMD) in 21.9% and Spinal Muscular Atrophy (SMA) in 12.5%, and myositis in 9.4%. Ultrasonography showed sensitivity in the diagnosis ... respectively…
Background: Spinal Muscular Atrophy (SMA) is a life-threatening autosomal recessive neuromuscular disorder, primarily caused by mutations in the SMN1 gene. Early detection of SMA through newborn screening ... then by…
products: Luxturna for a rare inherited retinal dystrophy, and Zolgensma for spinal muscular atrophy. The main challenge of making a rAAV gene therapy product is the development of a robust
unique opportunity to identify a rare genetic disorder, X-Linked Spinal Muscular Atrophy (XL-SMA), and to work with clinicians and families throughout the world to identify these rare families
leads to deterioration of ambulation, wheelchair dependency, and eventual respiratory and cardiac failure. Spinal Muscular Atrophy (SMA) is an autosomal recessive neuromuscular disease resulting in atrophy of the…
this gene are associated with Charcot Marie Tooth disease 2C (CMT 2C), scapuloperoneal spinal muscular atrophy and congenital distal spinal atrophy as well as various skeletal dysplasias. Associated features include
characterized by muscle weakness and degeneration, such as Duchenne Muscular Dystrophy (DMD) or Spinal Muscular Atrophy (SMA). A congenital condition where the spine and spinal cord do not develop properly
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis…
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease with dysfunctional α-motor neurons in the anterior horn of the spinal cord. SMA is caused by loss
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease with dysfunctional α-motor neurons in the anterior horn of the spinal cord. SMA is caused by loss
patients with underlying neuromuscular disorders such as cerebral palsy, muscular dystrophy, or spinal muscular atrophy. Non-ambulatory patients with NMS are particularly challenging to treat due to their limited…
vectors, CRISPR based gene editing, and successful treatments for inherited disorders such as spinal muscular atrophy and certain immunodeficiencies. Despite its great promise, challenges such as immune responses, off…
responsible for rare but severe neurological conditions, such as Huntington’s disease and spinal muscular atrophy (SMA). These discoveries have not only provided a deeper understanding of the molecular mechanisms
recent introduction of the innovative therapy with onasemnogene abeparvovec (Zolgensma®) revolutionized the spinal muscular atrophy (SMA) therapeutic landscape. Even if it had proven to lead to functional improvements
Almost 4% of spinal muscular atrophy affected patients (SMA) carry the deletion in one copy of the Survival Motor Neuron gene 1 (SMN1) and a deleterious point mutation
also seen such start-ups actively promote media awareness of a rare disease (Spinal Muscular Atrophy), fund six patients with a potential curative therapy, and through engaging celebritiesâÂ
knockdown Survival Motor Neurons (SMN) cells, and on cells of patients affected by Spinal Muscular Atrophy (SMA), to investigate whether SMN may play a role in the nucleolar reorganization during
innovative gene therapy for paediatric patients, Zolgensma (onasemnogene abeparvovec-xioi), for treating spinal muscular atrophy (SMA), one of the leading causes of infant mortality. In May 2019, researchers
products: Luxturna for a rare inherited retinal dystrophy, and Zolgensma for spinal muscular atrophy. The main challenge of making a rAAV gene therapy product is the development of a robust
replacement therapies for several disorders, including Leber congenital amaurosis type 2 (LCA2),1 spinal muscular atrophy type 1 (SMA1),2 and β-thalassemia.3 The latter result has the potential
vitro model for a number of genetic conditions, such as spinal muscular atrophy and familial dysautonomia , as well as inherited and sporadic forms of various human neurodegenerative conditions, including motor